Increased Levels of Antigen-Bound β-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer's Disease Patients

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Maftei, Madalina ^a   Thurm, Franka ^a,b,c   Schnack, Cathrin ^b   Tumani, Hayrettin ^b   Otto, Markus ^b   Elbert, Thomas ^a   Kolassa, Iris Tatjana ^a,b   Przybylski, Michael ^a   Manea, Marilena ^a   von Arnim, Christine A F ^b  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AUTOANTIBODY; IMMUNOGLOBULIN G; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; COGNITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; PROTEIN CEREBROSPINAL FLUID LEVEL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODY SPECIFICITY; AUTOANTIBODIES; COGNITION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MODELS, STATISTICAL;

EID: 84880404775     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068996     Document Type: Article

References (72)

1. Selkoe DJ, (2000) Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 924: 17-25.
2. Thal DR, Rüb U, Orantes M, Braak H, (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58: 1791-1800.
3. Braak E, Griffing K, Arai K, Bohl J, Bratzke H, et al. (1999) Neuropathology of Alzheimer's disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci Suppl. 249: 14-22.
4. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, et al. (2013) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12: 357-367.
5. Finder VH, Glockshuber R, (2007) Amyloid-beta aggregation. Neurodegener Dis 4: 13-27.
6. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982.
7. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985.
8. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T, (2001) Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 159: 439-447.
9. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
10. Bard F, Cannon C, Barbour R, Burke RL, Games D, et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916-919.
11. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, et al. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. PNAS 98: 8850-8855.
12. Dodart J-C, Bales KR, Gannon KS, Greene SJ, DeMattos RB, et al. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5: 452-457.
13. Morgan D, (2011) Immunotherapy for Alzheimer's disease. J Intern Med 269: 54-63.
14. Schenk D, (2002) Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3: 824-828.
15. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, et al. (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38: 547-554.
16. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216-223.
17. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562.
18. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M, (2010) Alzheimer's disease: clinical trials and drug development. Lancet Neurol 9: 702-716.
19. Garber K, (2012) Genentech's Alzheimer's antibody trial to study disease prevention. Nat Biotechnol 30: 731-732.
20. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, et al. (2009) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 30: 1728-1736.
21. Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, et al. (2008) Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 283: 4714-4722.
22. Du Y, Wei X, Dodel R, Sommer N, Hampel H, et al. (2003) Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 126: 1935-1939.
23. Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, et al. (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75: 1472-1474.
24. Bacher M, Depboylu C, Du Y, Noelker C, Oertel WH, et al. (2009) Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neurosci Lett 449: 240-245.
25. Jolles S, Sewell WAC, Misbah SA, (2005) Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142: 1-11.
26. Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, et al. (2011) Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci 31: 5847-5854.
27. Dodel R, Neff F, Noelker C, Pul R, Du Y, et al. (2010) Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 70: 513-528.
28. Song M, Mook-Jung I, Lee H, Min J, Park M, (2007) Serum anti-amyloid-beta antibodies and Alzheimer 's disease in elderly Korean patients. J Int Med Res 35: 301-306.
29. Weksler ME, Relkin N, Turkenich R, Larusse S, Ling Z, et al. (2002) Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 37: 943-948.
30. Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schulz C, Bürger K, et al. (2005) Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. Biol Psychiatry 57: 813-816.
31. Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, et al. (2004) Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 25: 1023-1032.
32. Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, et al. (2001) Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol 49: 808-810.
33. Baril L, Nicolas L, Croisile B, Crozier P, Hessler C, et al. (2004) Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects. Neurosci Lett 355: 226-230.
34. Du Y, Dodel R, Hampel H, Buerger K, Lin S, et al. (2001) Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57: 801-805.
35. Gustaw KA, Garrett MR, Lee H-G, Castellani RJ, Zagorski MG, et al. (2008) Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J Neurochem 106: 1350-1356.
36. Gustaw-Rothenberg K, Siedlak S, Bonda D, (2010) Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: A population-based study. Exp Gerontol 45: 47-52.
37. Klaver AC, Coffey MP, Smith LM, Bennett DA, Finke JM, et al. (2011) ELISA measurement of specific non-antigen-bound antibodies to Abeta1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects. J Neuroinflammation 8: 93.
38. Przybylski M, Stefanescu R, Manea M, Perdivara I, Cozma C, et al. (2007) New molecular approaches for immunotherapy and diagnosis of Alzheimer's disease based on epitope-specific serum beta-amyloid antibodies. 7th Austral. Pept. Symposium, Cairns, abstr. p. 32.
39. Dodel R, Bacher M, Przybylski M, Stefanescu R, Manea M (2008) Diagnosis of Alzheimer's disease and other neurodementing disorders. Patent International Application No.: PCT/IB2008/000456, Pub. No.: WO/2008/084402, European Patent Office. Available: http://ip.com/patapp/EP1944314A1. Accessed 13 November 2011.
40. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, et al. (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8: 1263-1269.
41. Maftei M, Thurm F, Leirer VM, Von Arnim C a F, Elbert T, et al. (2012) Antigen-bound and free β-amyloid autoantibodies in serum of healthy adults. PloS One 7: e44516.
42. Folstein MF, Folstein SE, McHugh PR, (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
43. Ihl R, Weyer G (1993) Die Alzheimer Disease Assessment Scale (ADAS). [The Alzheimer Disease Assessment Scale (ADAS).]. Beltz Test: Weinheim.
44. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
45. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. 4th ed. te. Washington, DC: Author.
46. Brettschneider J, Petzold A, Schottle D, Claus A, Riepe M, et al. (2006) The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord 21: 291-295.
47. Potapov S, Adler W, Lausen B (2009) Daim: Diagnostic accuracy of classification models. R package version 1.0.0. Available:http://cran.r-project.org/package=Daim. Accessed 8 August 2011.
48. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, et al. (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12: 77.
49. Lindsay J, Laurin D, Verreault R, Hébert R, Helliwell B, et al. (2002) Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156: 445-453.
50. Braak H, Braak E, (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
51. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, et al. (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12: 207-216.
52. Tapiola T, Alafuzoff I, Herukka S-K, Parkkinen L, Hartikainen P, et al. (2009) Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66: 382-389.
53. Zetterberg H, Blennow K, Hanse E, (2010) Amyloid beta and APP as biomarkers for Alzheimer's disease. Exp Gerontol 45: 23-29.
54. Mehta PD, (2007) Amyloid beta protein as a marker or risk factor of Alzheimer's disease. Curr Alzheimer Res 4: 359-363.
55. Irizarry MC, (2004) Biomarkers of Alzheimer disease in plasma. NeuroRx 1: 226-234.
56. Seppälä TT, Herukka S-K, Hänninen T, Tervo S, Hallikainen M, et al. (2010) Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 81: 1123-1127.
57. Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, et al. (2008) Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Brain Res 1219: 169-179.
58. Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, et al. (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 45: 537-541.
59. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, et al. (1999) Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 46: 412-416.
60. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, et al. (2003) Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60: 958-964.
61. Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, et al. (1996) Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 141: 65-68.
62. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP, (2001) Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 304: 102-106.
63. Mehta PD, Pirttila T, (2005) Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease. Neurodegener Dis 2: 242-245.
64. Fagan AM, Mintun MA, Mach RH, Lee S-Y, Dence CS, et al. (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59: 512-519.
65. Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, et al. (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57: 100-105.
66. Sundelöf J, Giedraitis V, Irizarry MC, Sundström J, Ingelsson E, et al. (2008) Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 65: 256-263.
67. Björkqvist M, Ohlsson M, Minthon L, Hansson O, (2012) Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One 7: e29868.
68. Holtzman DM, Herz J, Bu G, (2012) Apolipoprotein e and apolipoprotein e receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2: a006312.
69. Wang Y-J, Zhou H-D, Zhou X-F, (2006) Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 11: 931-938.
70. Li R, Lindholm K, Yang L-B, Yue X, Citron M, et al. (2004) Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. PNAS 101: 3632-3637.
71. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, et al. (2010) Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 7: 90.
72. Jianping L, Zhibing Y, Wei Q, Zhikai C, Jie X, et al. (2006) Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord 20: 127-132.